| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
CDK7/9 tide is a substrate for cyclin-dependent kinases CDK7 and CDK9. The peptide sequence is based on the C-terminal tail of RNA Polymerase II (sequence: YSPTSPSYSPTSPSYSPTSPSKKKK), which is the physiological target of these kinases. It is not an inhibitor but a substrate for measuring kinase activity.
|
|---|---|
| ln Vitro |
As a peptide substrate, CDK7/9 tide itself does not have inhibitory or toxic activity. It is used in vitro to measure the kinase activity of CDK7 and CDK9. In kinase assays, the incorporation of phosphate groups into the peptide is quantified as a measure of enzyme activity and to test the efficacy of kinase inhibitors.
|
| ln Vivo |
CDK7/9 tide is not a drug candidate and is not typically used in in vivo animal studies. It is exclusively a research tool for in vitro biochemical assays. It has no intrinsic biological activity in vivo and is not designed for systemic administration.
|
| Enzyme Assay |
For in vitro kinase assays, the CDK7/9 tide peptide is diluted in assay buffer (e.g., 20 mM MOPS, 25 mM beta-glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM DTT). A master mix containing peptide, ATP (including 33P-ATP or 32P-ATP), and kinase is prepared. The reaction is incubated at 30degC for 15-30 minutes and spotted onto P81 filter paper, washed, and counted in a scintillation counter.
|
| Cell Assay |
No cellular assays are performed with CDK7/9 tide as it is a peptide substrate for in vitro biochemical assays, not a cell-permeable compound. It would not enter cells in significant quantities and is used exclusively in cell-free systems. For cellular studies of CDK activity, alternative methods such as Western blotting for phospho-RNA Pol II are recommended.
|
| Animal Protocol |
CDK7/9 tide is not used in animal studies as it is a research tool for in vitro assays only. It is not designed for in vivo administration and has no therapeutic application. It is a biochemical reagent used for drug screening and mechanistic studies of CDK7 and CDK9 in cell-free systems.
|
| ADME/Pharmacokinetics |
CDK7/9 tide is a peptide reagent with no pharmacokinetic properties of relevance as it is not administered to living organisms. It is used exclusively in in vitro biochemical assays where it is present in the reaction buffer. Its stability is maintained by storing lyophilized powder at -20degC and preparing fresh solutions for each experiment.
|
| Toxicity/Toxicokinetics |
CDK7/9 tide is considered non-toxic for its intended use as a research reagent. Standard laboratory safety practices should be followed when handling the lyophilized powder. It is not intended for human or animal consumption and should not be administered to patients.
|
| References | |
| Additional Infomation |
CDK7/9 tide is a synthetic peptide with sequence YSPTSPSYSPTSPSYSPTSPSKKKK. The peptide is derived from the C-terminal tail of RNA Polymerase II and is a substrate for CDK7, CDK8, CDK9, and CDK11. It is commonly used in high-throughput kinase inhibitor screening assays due to its specificity. Purity is ≥95% by HPLC, and it is stored as a lyophilized powder at -20degC for up to one year.
|
| Molecular Formula |
C120H185N29O41
|
|---|---|
| Molecular Weight |
2690.00
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~10 mg/mL (~3.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3717 mL | 1.8587 mL | 3.7175 mL | |
| 5 mM | 0.0743 mL | 0.3717 mL | 0.7435 mL | |
| 10 mM | 0.0372 mL | 0.1859 mL | 0.3717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
